Female Sexual Dysfunction
Female sexual dysfunction (FSD) affects approximately 43% of American women, with 12% experiencing distress significant enough to meet criteria for a sexual disorder; distress peaks at ~15% among women aged 45–64 years.[1] ACOG recommends that obstetrician-gynecologists initiate clinical discussion of sexual function during routine care visits to identify issues and destigmatize the topic.[1] For urogynecologists and pelvic reconstructive surgeons, FSD intersects with daily practice — dyspareunia and genito-pelvic pain drive surgical referrals, vaginal estrogen is a perioperative adjunct, and many patients undergoing prolapse or incontinence repair have overlapping sexual concerns that require evaluation and counseling.
Acronym reference
The female sexual-medicine literature is acronym-dense. The full expansions used on this page:
| Acronym | Expansion |
|---|---|
| FSD | Female Sexual Dysfunction |
| HSDD | Hypoactive Sexual Desire Disorder |
| FSIAD | Female Sexual Interest / Arousal Disorder |
| GPPPD | Genito-Pelvic Pain / Penetration Disorder |
| PGAD | Persistent Genital Arousal Disorder |
| GSM | Genitourinary Syndrome of Menopause |
| DSM-5 | Diagnostic and Statistical Manual of Mental Disorders, 5th edition |
| ISSWSH | International Society for the Study of Women's Sexual Health |
| ICSM | International Consultation on Sexual Medicine |
| ACOG | American College of Obstetricians and Gynecologists |
| FSFI | Female Sexual Function Index (validated symptom-burden instrument) |
| FSDS | Female Sexual Distress Scale |
| SSE | Satisfying Sexual Event (the standard outcome metric across HSDD trials) |
| CBT | Cognitive Behavioral Therapy |
| PFPT | Pelvic Floor Physical Therapy |
| SERM | Selective Estrogen Receptor Modulator |
| DHEA | Dehydroepiandrosterone |
| SSRI / SNRI | Selective Serotonin / Serotonin-Norepinephrine Reuptake Inhibitor |
Prevalence and epidemiology
FSD is highly prevalent, with an estimated overall prevalence of 39–50% for sexual symptoms and ~12–20% for clinically distressing dysfunction.[2][3][4] A 2024 NEJM review highlighted that low desire progressively increases with age, but sexually associated distress concurrently declines, so that the peak in hypoactive sexual desire disorder (HSDD) emerges during midlife.[5] In a large Australian community-based study, 27.4% of women aged 18–24 and 58.9% of women aged 45–49 had low desire, but distressing dysfunction peaked in the middle-age groups.[5]
Arousal dysfunction affects approximately 3–9% of women aged 18–44 and 5–7.5% of women aged 45–64.[5] Among young women (18–39 years), 20.6% have at least one FSD, with sexual self-image dysfunction (11.1%) the most prevalent subtype. Psychotropic medication use was significantly associated with all FSD subtypes in this population.[4]
DSM-5 classification
The DSM-5 identifies four types of female sexual dysfunction.[1][6] All diagnoses require ≥6 months duration (except substance-induced), clinically significant personal distress, and exclusion of another mental disorder, relationship distress, or medical condition as primary explanation.
| DSM-5 Disorder | Core features |
|---|---|
| Female Sexual Interest/Arousal Disorder (FSIAD) | Absent/reduced interest, thoughts/fantasies, initiation/responsiveness, excitement, or genital/nongenital sensations during activity |
| Female Orgasmic Disorder | Absent, delayed, infrequent, or markedly reduced intensity of orgasm |
| Genito-pelvic Pain/Penetration Disorder (GPPPD) | Difficulty with penetration, vulvovaginal/pelvic pain, fear/anxiety about pain, or pelvic floor muscle tensing; combines former diagnoses of vaginismus and dyspareunia |
| Substance/Medication-Induced Sexual Dysfunction | Temporally linked to a substance or medication |
The International Society for the Study of Women's Sexual Health / International Consultation on Sexual Medicine (ISSWSH / ICSM) classification separates desire from arousal (cognitive vs genital arousal), adds persistent genital arousal disorder (PGAD), and further expands orgasm-disorder subtypes by frequency, intensity, timing, and pleasure dimensions.[2] Pain disorders are classified identically between the two systems.
Evaluation
The initial evaluation may require an extended visit and should include a comprehensive history and physical examination.[1] A detailed sexual history should cover:
- Sexual and gender identity
- Symptom nature, duration, and onset (acquired vs. lifelong; generalized vs. situational)
- Personal distress level
- Partner factors and relationship quality
- History of abuse or trauma
- Genito-pelvic activities and injuries
- Sleep quality and body image concerns
Validated instruments: Female Sexual Function Index (FSFI) and Female Sexual Distress Scale (FSDS) are useful adjuncts for quantifying symptom burden and tracking treatment response.[1] The Decreased Sexual Desire Screener (DSDS) is a 5-item ~ 2-minute non-specialist HSDD screener (sensitivity 83.6–96.0% / specificity 87.8%); the SIDI-F-SR quantifies HSDD severity for treatment-response monitoring; the PROMIS SexFS v2.0 is the only instrument with dedicated vulvar-discomfort scales; the PISQ-IR is the condition-specific tool for pelvic-floor-disorder cohorts (uniquely captures sexual inactivity). For the full instrument catalog with comparison table, scoring details, psychometric data, and a "which instrument when" practical-guidance block see Assessment Tools — Female Sexual Function.
Laboratory testing is typically not necessary unless an undiagnosed medical etiology is suspected.[1]
Risk factors and contributing conditions
FSD is multifactorial, requiring a biopsychosocial framework:[2][5]
- Biological: menopause / hypoestrogenism (genitourinary syndrome of menopause, GSM), diabetes, cardiovascular disease, neurologic conditions, pelvic-floor dysfunction, endometriosis, chronic pain, surgical history (hysterectomy, oophorectomy)
- Medications: SSRIs/SNRIs, antipsychotics, hormonal contraceptives, antiepileptics, opioids, antihypertensives
- Psychological: depression, anxiety, history of sexual trauma, body image concerns, stress
- Relational: partner sexual dysfunction, relationship conflict, communication barriers
- Sociocultural: cultural/religious beliefs, inadequate sex education
ACOG evidence-graded recommendations
Level A (good and consistent evidence)[1]
- Low-dose vaginal estrogen is the preferred hormonal treatment for FSD due to GSM
- Low-dose systemic hormone therapy (estrogen ± progestin) is an alternative for women with both dyspareunia from GSM and vasomotor symptoms
- Ospemifene is an alternative to vaginal estrogen for dyspareunia caused by GSM
- Systemic DHEA is not effective and is not recommended for sexual interest/arousal disorders
Level B (limited or inconsistent evidence)[1]
- Psychological interventions (cognitive behavioral therapy [CBT], mindfulness-based therapy, couples therapy, sexual skills training) are recommended as part of treatment
- Short-term transdermal testosterone can be considered for postmenopausal women with sexual interest / arousal disorders after appropriate counseling about risks and unknown long-term effects
- Flibanserin can be considered for HSDD in premenopausal women without depression, with counseling about alcohol-related risks
- Intravaginal prasterone, low-dose vaginal estrogen, and ospemifene can all be used for moderate-to-severe dyspareunia from GSM
- Sildenafil should not be used for female interest/arousal disorders outside clinical trials
- Vaginal CO₂ laser should not be used outside a research setting
Level C (consensus/expert opinion)[1]
- Pelvic floor physical therapy is recommended for genito-pelvic pain/penetration disorders
- Lubricants, topical anesthesia, and moisturizers may help reduce dyspareunia
- If transdermal testosterone is used, a 3–6 month trial is recommended with baseline and follow-up testosterone levels to confirm levels remain in the normal premenopausal range; discontinue at 6 months if no response
Pharmacologic treatments
Flibanserin (Addyi)
FDA-approved for acquired, generalized HSDD in premenopausal women only.[7] Mechanism — modulates serotonin, dopamine, and norepinephrine pathways (5-HT1A agonist / 5-HT2A antagonist). Efficacy is modest: a meta-analysis of 8 trials (5,914 participants) showed an increase of ~ 0.5 satisfying sexual events (SSEs) per month over placebo, with significant side effects including dizziness, somnolence, nausea, and fatigue.[5] Alcohol must be avoided within 2 hours of dosing due to risk of hypotension and syncope; contraindicated with strong CYP3A4 inhibitors or hepatic impairment.[2] See the Flibanserin pharmacology page for the full prescribing framework.
Bremelanotide (Vyleesi)
FDA-approved for acquired, generalized HSDD in premenopausal women.[8] Mechanism — melanocortin-4 receptor agonist administered subcutaneously (1.75 mg) as needed ~ 45 minutes before anticipated sexual activity. The RECONNECT phase 3 trials (n = 1,267) demonstrated statistically significant improvements in desire (FSFI-desire domain increase of 0.35 over placebo, p < 0.001) and reductions in distress.[9] The most common adverse effects are nausea (40%), flushing (21%), and headache (12%).[10] The 52-week open-label extension showed sustained improvements with no new safety signals,[10] and efficacy was consistent across age, weight, BMI, and baseline testosterone subgroups.[11] See the Bremelanotide pharmacology page for the full prescribing framework.
Transdermal testosterone
The only evidence-based indication for testosterone in women is postmenopausal HSDD, per the 2019 Global Consensus Position Statement.[12] A meta-analysis of 36 RCTs (8,480 participants) showed testosterone significantly increased SSEs by ~ 0.85/month, with improvements in desire, arousal, orgasm, pleasure, and reduced distress.[13]
No FDA-approved female testosterone formulation exists in the United States. A transdermal 1% testosterone cream is approved in Australia.[5] When prescribed off-label, a fractionated dose of a regulator-approved male formulation is preferred over compounded preparations, with regular monitoring of serum testosterone and clinical assessment for androgen excess.[5][12] More than 2 million testosterone prescriptions are written annually for women in the US.[5] Oral testosterone adversely affects HDL and LDL cholesterol; transdermal routes are preferred.[5][13] Side effects include acne, increased facial / body hair, and weight gain; long-term safety data are lacking.[12] A 2025 review confirmed that two clinical guidelines now provide expert guidance on testosterone treatment and monitoring for HSDD in women.[14] See the Female Testosterone for HSDD pharmacology page for the full prescribing and monitoring framework.
Non-pharmacologic treatments
A 2025 systematic review and meta-analysis confirmed that mindfulness-based CBT significantly improved total FSFI scores and subscales of desire, arousal, and orgasm, and that all three modalities — CBT, flibanserin, and bremelanotide — reduced distress.[15] No studies have yet directly compared CBT to pharmacotherapy.
| Modality | Target disorder | Evidence level | Notes |
|---|---|---|---|
| CBT / mindfulness-based therapy | Desire, arousal, orgasm | Level B | Significant FSFI improvement; first-line for psychogenic disorders. MBI ranked first for sexual distress in the 2026 Qiangzhao NMA.[15] |
| Couples therapy / sex therapy / PLISSIT | Desire, arousal, relational | Level B | Addresses partner and communication factors. PLISSIT ranked first for FSFI improvement in the 2026 Qiangzhao NMA.[1] |
| Pelvic floor physical therapy | GPPPD | Level C | First-line for pain/penetration disorders[1] |
| Vaginal dilators | GPPPD / introital narrowing | Level C | Adjunct to PFPT[1] |
| Lubricants / moisturizers | Dyspareunia | Level C | OTC; adjunctive to all strategies[1] |
Treatment summary
Each pharmacologic row links to its dedicated pharmacology page for the full prescribing framework — dosing, contraindications, monitoring, and counseling details.
| Treatment | Indicated disorder | Route | Key data | Notable risks |
|---|---|---|---|---|
| Vaginal estrogen | Dyspareunia (GSM) | Vaginal | Level A; gold standard for postmenopausal dyspareunia[1] | Minimal systemic absorption at low doses |
| Ospemifene | Dyspareunia (GSM); OAB | Oral | Level A / B; SERM with vaginal agonist + breast antagonist activity[1] | Fluconazole interaction (2.7× AUC); take with food |
| Vaginal DHEA (prasterone) | Dyspareunia (GSM); FSIAD | Vaginal | Level B; improves all 6 FSFI domains[1] | No systemic E2 elevation (AI-user safe) |
| Flibanserin | HSDD (premenopausal) | Oral daily | +0.5 SSE/month over placebo[5] | Alcohol contraindication; CYP3A4 interactions; hepatic-impairment contraindication |
| Bremelanotide | HSDD (premenopausal) | SC injection on demand | +0.35 FSFI desire over placebo (RECONNECT)[9] | Nausea 40%; flushing 21%; uncontrolled-HTN contraindication |
| Transdermal testosterone | HSDD (postmenopausal) | Transdermal | +0.85 SSE/month (36 RCT meta-analysis)[13] | Androgen excess; no FDA approval in US; long-term safety unknown |
| CBT / mindfulness | Desire, arousal, orgasm | — | Significant FSFI improvement[15] | None |
| Pelvic floor PT | GPPPD | — | Level C consensus[1] | None |
See Also
Female sexual dysfunction context.
- Assessment Tools — Female Sexual Function — full validated-instrument catalog (FSFI / FSDS-R / DSDS / SIDI-F / PROMIS SexFS / PISQ-IR) with scoring details, psychometric data, and "which instrument when" practical-guidance block.
- Genitourinary Syndrome of Menopause — GSM as the most common biological substrate for dyspareunia and arousal disorder in postmenopausal women.
- Recurrent UTI — vaginal estrogen first-line for postmenopausal rUTI prevention.
- Chronic Pelvic Pain — GPPPD, vulvodynia, and pelvic-floor myofascial pain as overlapping diagnoses.
- Pelvic Floor Physical Therapy — first-line for GPPPD.
Pharmacology hubs — HSDD agents.
- Flibanserin (Addyi) — premenopausal HSDD daily oral; alcohol-related boxed warning; CYP3A4 contraindications.
- Bremelanotide (Vyleesi) — premenopausal HSDD on-demand SC; RECONNECT phase 3; uncontrolled-HTN contraindication.
- Female Testosterone for HSDD — postmenopausal off-label transdermal; 2019 Global Consensus; Islam 2019 Lancet Diabetes Endocrinol meta.
Pharmacology hubs — GSM and dyspareunia agents.
- Vaginal & Topical Estrogen — formulations, systemic-absorption gradient, breast-cancer safety data.
- Vaginal DHEA (Prasterone) — intracrinology mechanism; FSFI domain profile; AI-user safety.
- Ospemifene — oral SERM; OAB / UUI off-label evidence; drug interactions.
- Preoperative Hormonal Priming — IMPROVE trial; local estrogen before pelvic-floor surgery.
References
1. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. "Female Sexual Dysfunction: ACOG Practice Bulletin Clinical Management Guidelines, Number 213." Obstet Gynecol. 2019;134(1):e1–e18. doi:10.1097/AOG.0000000000003324
2. Dalrymple SN, Hoeg L, Thacker H. "Female Sexual Dysfunction: Common Questions and Answers." Am Fam Physician. 2025;111(5):433–442.
3. Vechiu C, Zimmermann M, Aubuchon-Endsley N, et al. "Female Sexual Dysfunction in Primary Care: A Systematic Review and Meta-Analysis of Prevalence." J Womens Health. 2025. doi:10.1177/15409996251410095
4. Zheng J, Skiba MA, Bell RJ, Islam RM, Davis SR. "The Prevalence of Sexual Dysfunctions and Sexually Related Distress in Young Women: A Cross-Sectional Survey." Fertil Steril. 2020;113(2):426–434. doi:10.1016/j.fertnstert.2019.09.027
5. Davis SR. "Sexual Dysfunction in Women." N Engl J Med. 2024;391(8):736–745. doi:10.1056/NEJMcp2313307
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Association; 2022.
7. U.S. Food and Drug Administration. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
8. Dhillon S, Keam SJ. "Bremelanotide: First Approval." Drugs. 2019;79(14):1599–1606. doi:10.1007/s40265-019-01187-w
9. Kingsberg SA, Clayton AH, Portman D, et al. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials." Obstet Gynecol. 2019;134(5):899–908. doi:10.1097/AOG.0000000000003500
10. Simon JA, Kingsberg SA, Portman D, et al. "Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder." Obstet Gynecol. 2019;134(5):909–917. doi:10.1097/AOG.0000000000003514
11. Simon JA, Kingsberg SA, Portman D, et al. "Prespecified and Integrated Subgroup Analyses From the RECONNECT Phase 3 Studies of Bremelanotide." J Womens Health. 2022;31(3):391–400. doi:10.1089/jwh.2021.0225
12. Davis SR, Baber R, Panay N, et al. "Global Consensus Position Statement on the Use of Testosterone Therapy for Women." J Clin Endocrinol Metab. 2019;104(10):4660–4666. doi:10.1210/jc.2019-01603
13. Islam RM, Bell RJ, Green S, Page MJ, Davis SR. "Safety and Efficacy of Testosterone for Women: A Systematic Review and Meta-Analysis of Randomised Controlled Trial Data." Lancet Diabetes Endocrinol. 2019;7(10):754–766. doi:10.1016/S2213-8587(19)30189-5
14. Kling JM. "Testosterone for the Treatment of Hypoactive Sexual Desire Disorder in Perimenopausal and Postmenopausal Women." Obstet Gynecol. 2025. doi:10.1097/AOG.0000000000006015
15. Toledo RG, Winkelman WD, Reyes-Gonzalez D, et al. "Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options." J Minim Invasive Gynecol. 2025. doi:10.1016/j.jmig.2025.06.004